Introduction
============

Vascular endothelial growth factor (VEGF) has vasodilatory effects so is used by vascular surgeons to treat ischemic diseases,[@b1-opth-6-343] and intravitreal VEGF antagonists are now being used by ophthalmologists to treat various ischemic retinal disorders.[@b2-opth-6-343],[@b3-opth-6-343] Several studies report that fluorescein angiographic findings are absent following the administration of intravitreal bevacizumab or ranibizumab.[@b4-opth-6-343]--[@b9-opth-6-343] Preliminary case series reported by some researchers suggest the possibility of a temporal link between these injections and subsequent retinal vascular events.[@b10-opth-6-343]--[@b21-opth-6-343] In the current study additional data that was contributed by various collaborators and supplemented by the literature[@b22-opth-6-343]--[@b44-opth-6-343] is presented to further analyze the possible relationship between anti-VEGF injections and ocular vascular accidents. Additionally, the current study provides information regarding the characterization of patients developing ocular vascular complications after intravitreal injections of anti-VEGF drugs.

Methods
=======

The current study is a retrospective survey among members of the American Society of Retinal Specialists who were invited to contribute a detailed protocol of cases that had vascular occlusions (central retinal artery occlusion \[CRAO\], branch retinal artery occlusion \[BRAO\], capillary occlusion, central retinal vein occlusion \[CRVO\], branch retinal vein occlusion \[BRVO\], anterior ischemic optic neuropathy \[AION\], and ocular ischemic syndrome) following anti-VEGF therapy. This research was approved by the Institutional Research Board (Rafic Hariri University Hospital, an affiliate of the American University of Beirut). Each center received Ethical Committee approval for the use of anti-VEGF for specific use and data analyses. The data collected included risk factors for vascular occlusion (carotid disease, coronary artery disease, systemic hypertension, diabetes mellitus, migraine, smoking, and glaucoma), the intraocular pressure on discharge, and the time period from intravitreal injection to detection of the vascular event. The total number of injections per investigator was also recorded.

A 14-month prospective study was also performed at Mansoura University using intravitreal bevacizumab. This included 42 patients, 33 of whom had proliferative diabetic retinopathy, seven with age-related macular degeneration, and two with central retinal vein occlusion. The study was approved by the Ethical Committee of Mansoura University.

Additionally, all studies in the literature regarding treatments with ranibizumab, bevacizumab, pegaptanib, and aflibercept as listed in PubMed and Scopus prior to August 2011 were searched for reports of adverse effects. As well as this, detailed reports of adverse effects of anti-VEGF medications sent to the FDA prior to April 2011 were retrieved via patientsville.com (for reports submitted from 2006 to 2009) and eHealthme.com (for reports submitted from 2010 to 2011), and retinal vascular events were selected for the current study.

Digital fundus photography and computerized determination of retinal trunk vessel diameters were performed using the previously described software.[@b3-opth-6-343],[@b45-opth-6-343],[@b46-opth-6-343] For each case the pre- and post-anti-VEGF treatment fundus photographs were analyzed using custom computer software. For each case a grader (PKK) chose at least two artery segments and two vein segments that were deemed the most suitable for analysis based on image quality, contrast, straightness of the vessel, absence of branching, and absence of vessel crossings. Images of these vessel segments taken before and after anti-VEGF treatment were analyzed for each case. Images were considered non-gradable if the image was of poor quality (low contrast), as judged by the grader. When necessary, images were calibrated by scaling them so that they were of equal size. Results were presented as the relative change in vessel diameter following anti-VEGF treatment.

Results
=======

A total of 144 cases were available for this study, which included 32 cases retrieved from the literature, 64 reports to the Food and Drug Administration (FDA), and 48 cases contributed from 22 centers across Africa, America, Asia, and Europe ([Tables 1](#t1-opth-6-343){ref-type="table"} and [2](#t2-opth-6-343){ref-type="table"}). Eight of these cases were part of a prospective study at Mansoura University (Mansoura City, Egypt) of 42 patients treated with intravitreal bevacizumab (33 patients with advanced proliferative diabetic retinopathy, seven with choroidal neovascularization, and two with central retinal vein occlusion). From 1665 reports of adverse effects following treatment with ranibizumab, 7167 reports of adverse effects following treatment with bevacizumab, 355 reports of adverse effects following treatment with pegaptanib, and 74 reports of adverse effects following treatment with aflibercept (VEGF Trap), the current study collected data on twelve ranibizumab-, 28 bevacizumab-, and six pegaptanib-related retinal vascular events.

Overall, 30 received ranibizumab, 9 pegaptanib and 106 bevacizumab (of which 13 received systemic bevacizumab, one received intracameral bevacizumab, one received 0.625 mg intravitreal bevacizumab, six received 2.5 mg intravitreal bevacizumab, and 55 received 1.25 mg intravitreal bevacizumab). The patient's gender was not always specified, but of those patients for whom this was specified there were 53 males and 55 females. In 95 patients, the median age was 67 (range = 0--95 years; mean = 64.5 years). Vascular events were diagnosed a median of 15 days after treatment (n = 56; range = 0--60 days). The median number of prior injections was one (range = 0--34). The right eye was involved in 30 patients, and the left eye in 28 patients (five patients had bilateral events, while the side was not specified for the remainder).

A majority of patients had preexisting risk factors for cardiovascular events. More specifically, diabetes mellitus was documented in a total of 44 patients. There were 37 diabetic patients in the combined group of 80 patients from the collaborative study and the literature review, ie, 46.3% of the combined group had diabetes mellitus. Other systemic disorders of the whole series included systemic hypertension in 31 patients, coronary heart disease in 16, and carotid artery disease in eight. Moreover, nine patients had a prior history of glaucoma. Mean initial intraocular pressure was 15.5 mm Hg (range = 7--24 mm Hg), and on discharge this was 21.5 mm Hg (range = 11--50 mm Hg) (n = 32). Paracentesis was performed in only three cases after the injection to reverse post-injection ocular hypertension and to facilitate retinal perfusion as assessed by indirect ophthalmoscopy (two eyes had neovascular glaucoma, and one eye had central retinal artery occlusion at a post-injection pressure of 21 mm Hg).

The major ocular conditions under therapy included diabetic retinopathy in 39 patients (21 with proliferative retinopathy and twelve with background retinopathy), wet age-related macular degeneration in 25, and retinal venous occlusion in 18 (13 central and five branch varieties). The ocular vascular events registered were ocular vascular occlusions (of an unspecified type in 30 cases), ipsilateral central retinal artery occlusion (19 cases), contralateral central retinal artery occlusion (one case), branch retinal artery occlusion (four cases), unspecified retinal artery occlusion (14 cases), ophthalmic artery occlusion (two cases), choroidal ischemia (one case), retinal capillary occlusion (31 cases, 19 of which were causing macular ischemia), central retinal vein occlusion (three cases), branch retinal vein occlusion (four cases), unspecified retinal vein occlusion (twelve cases), retinal artery spasm (two cases), anterior ischemic optic neuropathy (16 cases), ischemic optic neuropathy (four cases), and one case of vision loss of unspecified origin ([Tables 1](#t1-opth-6-343){ref-type="table"} and [2](#t2-opth-6-343){ref-type="table"}).

The median follow-up time in 48 patients was 3 months (average = 8 months; range = 1--36 months). Mean visual acuity (log Mar) dropped by 6.4 lines from 0.85 (20/142; median = 0.7) to 1.49 (20/618; median = 1.0) (Student's *t*-test n = 62; *P* = 0.0002). 40 eyes lost vision, ten eyes maintained vision, and 15 eyes gained vision at the last carried examination. Severe visual loss after injection to no light perception (NLP) occurred in five eyes, light perception (LP) in six eyes, and hand motion (HM) in three eyes.

Ocular vascular events occurred during anti-VEGF therapy in eight of 42 of patients (19.0%) in this selective prospective study. Overall in 26 centers, 55 ocular vascular events were reported among a total of 51,152 patients (0.108%) that received intravitreal anti-VEGF therapy ([Tables 1](#t1-opth-6-343){ref-type="table"} and [2](#t2-opth-6-343){ref-type="table"}). Eight ocular vascular events were reported in five centers among a total of 5340 patients (0.149%) that received intravitreal bevacizumab therapy. In the subset of the population who were diabetic, 15 ocular vascular events were reported in four centers from a total of 575 patients (2.61%; [Tables 1](#t1-opth-6-343){ref-type="table"} and [2](#t2-opth-6-343){ref-type="table"}). In one center, two cases of retinal vascular occlusions followed intravitreal VEGF antagonists from a total of 300 retinovascular occlusion cases examined. In a double blind randomized prospective study, two patients (2%) developed retinovascular events among 102 diabetics with macular edema treated with intravitreal ranibizumab, while there were no events reported in the control group.[@b30-opth-6-343] Terui et al[@b37-opth-6-343] described the occurrence of capillary nonperfusion in four out of 58 eyes (6.9%) with branch retinal vein occlusion 1 month after intravitreal bevacizumab (note that this was minimal in three eyes and marked in one); it is unknown if this is related to the injection or part of the natural history of the ocular disease.

Retinal vasoconstriction was observed after both bevacizumab and ranibizumab injections. More specifically, vasoconstriction analyses were available in 13 of the submitted 20 eyes (seven eyes did not meet the requirements for a paired comparison; [Table 3](#t3-opth-6-343){ref-type="table"}). Vasoconstriction was measured between 7 and 30 days (median = 14 days) after injection of bevacizumab (1.25 mg) in 13 eyes. Mean retinal arterial constriction was 21% (standard deviation = 27%) and mean venous constriction was 8% (standard deviation = 30%). Four cases had prominent retinal arterial vasoconstriction of 78%, 57%, 54%, and 28%, while a fifth eye had 33% retinal venous constriction. Vasoconstriction was also measured in one eye that had intravitreal ranibizumab (0.5 mg), with 42% retinal arterial constriction and 16% retinal venous constriction reported.

Discussion
==========

The adverse events associated with systemic bevacizumab include hypertension, proteinuria, and thromboembolism.[@b44-opth-6-343],[@b47-opth-6-343] Mourad et al used intravital video microscopy to measure dermal capillary densities in the dorsum of the fingers of patients receiving systemic bevacizumab and showed endothelial dysfunction and rarefaction by laser Doppler flowmetry.[@b48-opth-6-343] The ocular vascular effects of VEGF antagonists are still unclear. Costa et al evaluated the safety of intravitreal bevacizumab injections for the management of macular edema due to ischemic central or hemicentral retinal vein occlusion, with no complications noted at the 25-week follow-up in seven patients.[@b49-opth-6-343] Neubauer et al tried to assess peripheral perfusion before and after intravitreal bevacizumab and described a significant improvement in retinal perfusion post injection in 19 patients with nonproliferative diabetic macular edema.[@b9-opth-6-343] Chung et al found no visual improvement in eyes with diabetic macular ischemia after intravitreal bevacizumab, and no worsening of macular ischemia was found (pers comm; Koh HJ, March 2010).[@b50-opth-6-343]

Evidence suggests that vessel diameter is influenced by the drug.[@b51-opth-6-343]--[@b53-opth-6-343] Retinal arteriolar diameter decreased by 4.6% ± 4.6% at day 7 and by 8.1% ± 3.2% at day 30 in eleven eyes with neovascular macular degeneration after treatment with intravitreal ranibizumab.[@b51-opth-6-343] Similarly, 1 month after ranibizumab was injected into ten eyes with macular degeneration, Mendrinos et al found a mean arterial vasoconstriction of 8.4% ± 3.2%.[@b52-opth-6-343] Sacu et al found significant retinal arterial and venous vasoconstriction with a significant reduction in retinal perfusion in 27 patients with retinal branch vein occlusion.[@b53-opth-6-343] Soliman et al used bevacizumab to treat ten eyes with diffuse diabetic macular edema, and found that the most pronounced changes in vessel diameter occurred in two patients with proliferative diabetic retinopathy.[@b3-opth-6-343] We measured a higher vasoconstrictor effect and some eyes had marked vasoconstriction. It is also possible that there is a shift from vessel dilation driven by ischemia to constriction induced by VEGF antagonists, hence the large constrictive response which is reported.

Treatment with intravitreal VEGF antagonists is accompanied by exacerbation of systemic hypertension[@b54-opth-6-343] and attenuation of systemic VEGF levels.[@b55-opth-6-343] This effect on the vascular tone may last for 3 weeks following intravitreal injections,[@b54-opth-6-343]--[@b56-opth-6-343] but Lee et al found that only 30-minute systolic values were significantly higher than baseline blood pressure after bevacizumab injection.[@b56-opth-6-343] It is possible that this acute rise in blood pressure may be related to the stress of the intravitreal injection. Some patients have a panic attack during the injection, others get hyperglycemia,[@b57-opth-6-343] while a few may develop a dendritic corneal ulcer following treatment.[@b58-opth-6-343]

Transient ocular hypertension after intravitreal injection of VEGF antagonists has been emphasized in many studies.[@b59-opth-6-343]--[@b62-opth-6-343] Persistent ocular hypertension is of recent concern and occurs in around 3.4% of eyes, usually following multiple injections.[@b62-opth-6-343] This may relate to the presence of silicone oil or other large particulate matter in the syringe, such as high molecular weight aggregates in repackaged bevacizumab. A considerable short-term rise in intraocular pressure occurs preferentially in hyperopic eyes[@b60-opth-6-343],[@b62-opth-6-343] and eyes with known glaucoma, so there is a need to monitor intraocular pressure and retinal perfusion especially in eyes with poor retinal circulation.[@b18-opth-6-343] Acute angle closure glaucoma may also be precipitated by intravitreal injections.[@b62-opth-6-343]

The risk of ocular vascular events during anti-VEGF therapy was 0.108% in the treatments considered in the current study. The low rate and the large variation in the occurrence of such events among the collaborating centers may be related to several factors including the retrospective nature of the study, the ocular pathology bias, the natural history of ocular disease, and the absence of precisely scheduled fluorescein angiographic studies. Performing detailed eye examinations with fundus photography and fluorescein angiography initially, at 1 week, and 1 month post-injection in a prospective setting (such as in the prospective study from Mansoura University) yielded higher rates of ocular events than were reported following retrospective quick screening examinations at the time of repeated injections. Many of the reported events were asymptomatic, such as capillary occlusion outside the fovea, and minor branch retinal artery or vein occlusion. In the RESOLVE study, a total of 102 cases having ranibizumab injections for diabetic maculopathy resulted in two cases with retinal vascular events (capillary and arterial occlusions).[@b30-opth-6-343] In the ROCC study, one of the 16 patients with central retinal vein occlusion developed central retinal artery occlusion.[@b63-opth-6-343] Branch retinal artery occurred in one out of twelve consecutive patients with proliferative diabetic retinopathy following intravitreal bevacizumab.[@b32-opth-6-343] In the ANCHOR[@b64-opth-6-343] and MARINA[@b65-opth-6-343] studies (280 and 477 patients, respectively), no retinal vascular events were noted after 2 years of repeated intravitreal ranibizumab for the wet form of age-related macular degeneration. Prior prospective studies and the current survey found that eyes with wet age-related macular degeneration had the lowest frequencies of vascular events (0%--0.3%)[@b5-opth-6-343],[@b65-opth-6-343] while eyes with a greater number of ischemic vascular diseases such as proliferative diabetic retinopathy yielded a higher frequency of retinal vascular events (2%--19%, as in the current prospective study).[@b30-opth-6-343] The occurrence of ocular vascular occlusions after anti-VEGF medications was 2.61% in the diabetic population ([Tables 1](#t1-opth-6-343){ref-type="table"} and [2](#t2-opth-6-343){ref-type="table"}), almost 24 times the occurrence in the general population receiving VEGF antagonists ([Tables 1](#t1-opth-6-343){ref-type="table"} and [2](#t2-opth-6-343){ref-type="table"}).

Three studies show choroidal or retinal vaso-occlusion after intravitreal bevacizumab injections in experimental animals. Peters et al analyzed the acute intravitreal effects of bevacizumab in four cynomolgus monkeys and found that choriocapillaris endothelial cell fenestrations were significantly reduced, and that densely packed thrombocytes and leukocytes regionally occluded the choriocapillaris lumen of treated eyes.[@b66-opth-6-343] Schraermeyer et al found that bevacizumab immune complexes activate platelets and cause thrombosis in choroidal vessels of primate eyes.[@b67-opth-6-343],[@b68-opth-6-343] Ameri et al evaluated the effects of intravitreal bevacizumab in a rabbit retinal neovascularization model. An intravitreal VEGF injection was administered and intravitreal bevacizumab was then injected at day 2 and at week 1, and it was found that administration of intravitreal bevacizumab at week 1 resulted in severe capillary nonperfusion at week 2.[@b69-opth-6-343] Bonnin et al demonstrated ocular hypoperfusion after intravitreal bevacizumab in humans. In 15 patients with wet age-related macular degeneration, mean blood flow velocities were measured by ultrasound imaging before, and 4 weeks after, a single intravitreal injection of bevacizumab. Velocities decreased significantly in the central retinal, temporal posterior ciliary, and ophthalmic arteries by 10%, 20%, and 20% respectively.[@b60-opth-6-343],[@b70-opth-6-343] Sacu et al found significant vasoconstriction of retinal arteries and veins outside the area of nonischemic retinal branch vein occlusions as well as a significant reduction in the flow velocity of the retrobulbar central retinal artery.[@b53-opth-6-343]

The vascular events reported during VEGF antagonist therapies could be part of the natural history of the underlying ocular disease. A rise in blood pressure, stress of the procedure, the underlying systemic disease, and a sharp rise in intraocular pressure are variables that can be involved in some cases of ocular vascular events, and these variables can be detected and treated. A majority of the patients discussed in the current study had systemic diseases, particularly diabetes mellitus. VEGF antagonism could play a leader role in some cases that demonstrated vasoconstriction by analysis of vessel caliber. VEGF acts as a vessel dilator by stimulating nitric oxide synthesis, and influences the autoregulation in the microcirculation. If we block this rescuer, the retina may be damaged due to decreased retinal perfusion in the presence of a low ophthalmic systolic pressure. Because retinal vessel diameter is a useful surrogate for retinal perfusion, changes in the diameter of the retinal arterioles may indicate changes in retinal capillary blood flow. Thus, these findings suggest that VEGF antagonists may reduce retinal capillary blood flow, and caution should be exercised in the use of intravitreal VEGF inhibitors in eyes with severe ocular ischemia such as ocular ischemic syndrome with low ophthalmic systolic pressure or severe proliferative diabetic retinopathy.[@b11-opth-6-343],[@b15-opth-6-343] Further studies are needed to evaluate the incidence of vascular events during VEGF antagonist therapy in such high-risk patients.[@b11-opth-6-343]
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Collaborative and literature review of 106 cases of ocular vascular complications of the VEGF antagonist bevacizumab: clinical profile

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case N./sex/age                                Ocular vascular event after                         Dose used (mL)                     Paracentesis   IOP at discharge post injection   Prior IOP   Glaucoma   Primary eye disease                          Interval injection to detection of vascular occlusion (days)   N. prior injections   OD or OS   Visual acuity prior to vascular event (log MAR)   Visual acuity after vascular event (log MAR)   Follow up after ocular event (months)   Systemic disease and risk of the vascular event per submitting author (new cases per total number of injected patients)
  ---------------------------------------------- --------------------------------------------------- ---------------------------------- -------------- --------------------------------- ----------- ---------- -------------------------------------------- -------------------------------------------------------------- --------------------- ---------- ------------------------------------------------- ---------------------------------------------- --------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  **Arterial occlusion**                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  1/F/60                                         CRAO                                                Bevacizumab 2.5 mg                 No             30                                15          No         Ischemic CRVO/PDR/serous macular elevation   5                                                              1                     OD         CF3m (1.6)                                        20/60 (0.5)                                    4                                       HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      carotid stenosis\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/19,158

  2/F/74                                         CRAO                                                Bevacizumab 1.25 mg                No             NA                                10          No         Ischemic CRVO/serous macular elevation       14                                                             1                     OD         CF0.3m (2.5)                                      CF0.3m (2.5)                                   1                                       Smoker 1/19,158

  3/F/95                                         CRAO                                                Bevacizumab 1.25 mg                No             NA                                7           No         AMD                                          28                                                             4                     OD         20/50 (0.4)                                       LP (3.3)                                       5                                       HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      CAD 1/19,158

  4/M/49                                         CRAO                                                Bevacizumab 1.25 mg                Yes            21 before tap                     14          No         PDR/DM                                       0                                                              1                     OS         20/160 (0.9)                                      NLP (3.6)                                                                              DM 1/19,158

  5/F/47                                         CRAO                                                Bevacizumab 1.25 mg                No             14                                16          No         PDR/vitreous hemorrhage                      45                                                             1                     OD         20/200 (1)                                        HM (3)                                                                                 DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/2,000

  6/M/70                                         CRAO                                                Bevacizumab 1.25 mg                No             Nl                                Nl          No         CRVO                                         30                                                             1                     NA         20/200 (1)                                        CF0.3m (2.5)                                                                           HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/2,400 bevacizumab

  7/F/56                                         CRAO                                                Bevacizumab 1.25 mg                No             Nl                                Nl          No         CRVO                                         30                                                             1                     NA         20/80 (0.6)                                       HM (3)                                                                                 None\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/2,400 bevacizumab

  8/F/60                                         CRAO                                                Bevacizumab 2.5 mg                 No             NA                                12          Yes        CRVO                                         14                                                             0                     OD         20/20 (0.0)                                       HM (3)                                         6                                       

  9/M/73                                         CRAO                                                Bevacizumab 1.25 mg                No             16                                17          No         AMD                                          15                                                             1                     OD         20/100 (0.7)                                      20/400 (1.3)                                   15                                      HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Smoker\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/6,478 anti-VEGF

  10/F/72                                        CRAO                                                Bevacizumab 1.25 mg                No             19                                20          No         AMD                                          10                                                             1                     OD         20/160 (0.9)                                      20/250 (1.1)                                   18                                      HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Smoker\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      CAD\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/6,478 anti-VEGF

  11/74/F                                        CRAO                                                Bevacizumab 1.25 mg                No             \<25                              \<25        No         DM                                           2                                                              3                     NA         CF (1.6)                                          NLP (3.6)                                                                              DM/CAD

  12/52/F                                        CRAO                                                Bevacizumab 1.25 mg                No             20 mmHg                           20 mmHg     Yes        NVG                                          1                                                              1                     NA         20/200 (1)                                        NLP (3.6)                                                                              DM/HTN

  13[@b31-opth-6-343]                            CRAO                                                Bevacizumab                        NA             NA                                NA          NA         NA                                           NA                                                             NA                               20/1000 (1.7)                                     LP (3.3)                                                                               1/400 bevacizumab

  14/F/60[@b22-opth-6-343]                       CRAO                                                Bevacizumab1.25 mg intracameral    Yes            50                                20          Yes        PDR/NVG                                      30                                                             1                     OD         20/200 (1)                                        20/200 (1)                                     12r                                     DM

  15[@b27-opth-6-343]                            CRAO                                                Bevacizumab                        NA             NA                                NA          NA         NA                                           7                                                              NA                    NA         NA                                                NA                                                                                     1/5,228

  16/M/78                                        Contralateral CRAO                                  Bevacizumab 1.25 mg                NA             NA                                NA          NA         AMD                                          21                                                             0                     NA         CF0.3m (2.5)                                      CF1m (2)                                       3                                       Hypercholesterolemia, CAD post coronary bypass 3/2,400 bevacizumab

  17/M/44                                        BRAO                                                Bevacizumab 1.25 mg                No             Nl                                NA          No         Ischemic CRVO                                2                                                              1                     OD         20/125 (0.8)                                      CF2m (1.8)                                     9                                       HTN 1/2,400 anti-VEGF

  18/M/76                                        BRAO                                                Bevacizumab 1.25 mg                No             28                                12          No         AMD                                          NA                                                             13                    OD         20/400 (1.3)                                      20/50 (0.4)                                    24                                      HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      CAD\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Smoker\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/19,158

  19/M/45                                        BRAO                                                Bevacizumab systemic               No             16                                16          No         None                                         1                                                              1                     OS         20/100 (0.7)                                      20/50 (0.4)                                    3                                       HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      cancer

  20/F/53[@b32-opth-6-343]                       BRAO                                                Bevacizumab 1.25 mg                NA             NA                                NA          NA         PDR                                          14                                                             1                     OS         20/50 (0.4)                                       20/600 (1.5)                                   1                                       DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/12 PDR patients

  21/M/65                                        Retinal artery occlusion                            Bevacizumab                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 5096382-0

  22/M/80                                        Retinal artery occlusion                            Bevacizumab 2.5 mg                                                                                         DR                                                                                                                                                                                                                                                                                    DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 5105228-35105228-3

  23/F/60                                        Retinal artery occlusion                            Bevacizumab                                                                                     Yes                                                                                                                                                                                                                                                                                              Avastin Side Effects Report: 5536025-2

  24/F/x                                         Retinal artery occlusion                            Bevacizumab 15mg/kg q 3wk                                                                                                                                                                                                                                                                                                                                                                        Lung cancer on Navelbine\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 5593981-4

  25/M/x                                         Retinal artery occlusion                            Bevacizumab 1.25 mg                                                                                        CME                                                                                                                                                                                                                                                                                   Avastin Side Effects Report: 5736856-X, 5746319-3

  26/M/44                                        Retinal artery occlusion                            Bevacizumab 1.25 mg                                                                                        Retinal vein occlusion                                                                                                                                                                                                                                                                Avastin Side Effects Report: 6237313-7, 6237504-5, 6253539-0, 6253542-0, 6341872-3; 6358564-7

  **Venous occlusion**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  27/M/93                                        CRVO                                                Bevacizumab 1.25 mg                No             29                                15          Yes        AMD                                          10                                                             1                     OD         20/60 (0.5)                                       20/400 (1.3)                                   18                                      HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      CAD (stent; pacemaker)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Left carotid artery disease\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/19,158

  28/M/50[@b34-opth-6-343]                       CRVO                                                Bevacizumab systemic               NA             NA                                NA          NA         None                                         1 day after each cycle                                         NA                    OD         20/120 (0.8)                                      NA                                                                                     Metastatic adenocarcinoma of colon after 2 cycles of capecitabine, oxaliplatin and bevacizumab

  29/F/65[@b36-opth-6-343]                       CRVO-like picture                                   Bevacizumab 1.25 mg                No             NA                                NA          No         PDR                                          7                                                              0                     OD         20/400 (1.3)                                      20/200 (1)                                     9                                       DM

  30/F/79                                        BRVO                                                Bevacizumab 1.25 mg                No             32                                11          No         AMD                                          55                                                             1                     OS         20/30 (0.2)                                       20/30 (0.2)                                    18                                      HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      CAD\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Migraine\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      CVA\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/19,158

  31/M/65                                        BRVO                                                Bevacizumab 1.25 mg                No             22                                16          No         PDR/ischemic DM/vitreous hemorrhage          7                                                              0                     OS         CF2m (1.8)                                        20/200 (1)                                     3                                       HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/42 prospective study

  32/M/63                                        BRVO                                                Bevacizumab 1.25 mg                No             24                                16          No         PDR/ischemic DM                              7                                                              0                     OD         CF4m (1.5)                                        20/80 (0.6)                                    3                                       HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/42 prospective study

  33/premature baby[@b28-opth-6-343]             Inferior retinal vein sheathing (nonperfusion)      Bevacizumab 0.625 mg               NA             NA                                NA          No         Retinopathy of prematurity                   3                                                              0                     OU         NA                                                NA                                                                                     Retinopathy of prematurity\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/40 patients with retinopathy of prematurity

  34[@b39-opth-6-343]                            Retinal vein occlusion                              Bevacizumab 1.25 mg                NA             NA                                NA          NA         AMD                                          NA                                                             NA                    NA         NA                                                NA                                                                                     1/300 of wet AMD

  35[@b39-opth-6-343]                            Retinal vein occlusion                              Bevacizumab 1.2 mg                 NA             NA                                NA          NA         AMD                                          NA                                                             NA                    NA         NA                                                NA                                                                                     1/300 of wet AMD

  36/M/90                                        Retinal vein occlusion (ischemic)                   Bevacizumab 1.25 mg                                                                                                                                                                                                                                                                                                                                                                              HTN, CAD, dyslipidemia\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 5197845-X, 5197968-5

  37/F/x                                         Retinal vein occlusion (ischemic)                   Bevacizumab 1.25 mg                                                                                                                                                                                                                                                                                                                                                                              Avastin Side Effects Report: 5508336-8, 5532270-0

  38/F/x                                         Retinal vein occlusion                              Bevacizumab 1.25 mg                                                                                        DR                                                                                                                                                                                                                                                                                    DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 5706126-4

  39/F/27                                        Retinal vein occlusion                              Bevacizumab                                                                                                Retinal neovascularization                                                                                                                                                                                                                                                            Side Effects Report: 6054515-3

  40/F/73                                        Retinal vein occlusion                              Bevacizumab 350 mg q2wk                                                                                                                                                                                                                                                                                                                                                                          Colon cancer on capecitabine, oxaliplatin\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 4839872-5, 4865570-8

  41/F/x                                         Retinal vein occlusion                              Bevacizumab 1000 mg q3wk                                                                                                                                                                                                                                                                                                                                                                         Lung cancer\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 6209258-X

  42/M/69                                        Retinal vein occlusion                              Bevacizumab                                                                                                CME                                                                                                                                                                                                                                                                                   Avastin Side Effects Report: 6440612-7

  43/M/72                                        Retinal vein occlusion                              Bevacizumab                                                                                                CME                                                                                                                                                                                                                                                                                   Avastin Side Effects Report: 6440613-9

  **Retinal vascular occlusion (unspecified)**                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  44/M/43                                        Retinal vascular disorder                           Bevacizumab 1 mg                                                                                           DR                                                                                                                                                                                                                                                                                    DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 5959710-7

  45/M/41                                        Retinal vascular disorder                           Bevacizumab 1 mg                                                                                           DR                                                                                                                                                                                                                                                                                    DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 5961890-4

  46/F/x                                         Retinal vascular disorder                           Bevacizumab 1 mg                                                                                           DR                                                                                                                                                                                                                                                                                    DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 6033375-0

  47/M/x                                         Retinal vascular disorder                           Bevacizumab 1 mg                                                                                           maculopathy                                                                                                                                                                                                                                                                           HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 6159169-3

  48/F/x                                         Retinal vascular disorder                           Bevacizumab 1 mg                                                                                                                                                                                                                                                                                                                                                                                 CAD, unstable angina\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 6291768-0

  49/M/75                                        Retinal vascular disorder                           Bevacizumab 1 mg                                                                                           DM                                                                                                                                                                                                                                                                                    DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 6438164-01^i^

  50/F/33                                        Retinal vascular disorder                           Bevacizumab                                                                                                Vitreous hemorrhage                                                                                                                                                                                                                                                                   Avastin Side Effects Report: 5724031-4

  51-59/9 cases above 40 years                   Retinal vascular disorder                           Bevacizumab                                                                                                mixed                                                                                                                                                                                                                                                                                 2010 events from eHealthMe drug outcomes from FDA and community

  **Optic neuropathy**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  60/F/72                                        AION                                                Bevacizumab 1.25 mg                No             NA                                12          No         AMD; fellow eye\                             7                                                              1                     OS         CF2m (1.8)                                        LP (3.3)                                       0.5                                     none 1/2,100 bevacizumab
                                                                                                                                                                                                                AION                                                                                                                                                                                                                                                                                  

  61/F/71                                        AION                                                Bevacizumab 1.25 mg                No             16                                20          No         AMD                                          60                                                             1                     OS         20/70 (0.55)                                      20/70 (0.55)                                   6                                       HTN 1/333

  62/M/51                                        AION                                                Bevacizumab 1.25 mg                No             NA                                NA          No         AMD                                          15                                                             1                     OD         20/25 (0.1)                                       20/25 (0.1)                                    12r                                     Pseudoxanthoma elasticum

  63/F/38                                        AION                                                Bevacizumab 1.25 mg                No             21                                23          Yes        DM                                           21                                                             0                     OS         20/40 (0.3)                                       20/25 (0.1)                                    14                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/150 bevacizumab

  64/F/70                                        AION                                                Bevacizumab 1.25 mg                No             Nl                                Nl          No         AMD                                          28                                                             3                     OD         20/60 (0.5)                                       20/120 (0.8)                                   6                                       None\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/500 bevacizumab

  65/M/86                                        AION                                                Bevacizumab 2.5 mg                 No                                                           No         AMD                                          30                                                             14                    OD         20/70 (0.55)                                      20/100 (0.7)                                   12                                      HTN, prostate cancer, esophageal cancer, on amlodipine\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/6000 injection anti-VEGF

  66/F/92                                        AION                                                Bevacizumab 2.5 mg                                                                                         AMD                                                                                                         8                     OS         20/70 (0.55)                                      20/100 (0.7)                                   48                                      No significant past medical history, on no medications

  67/M/70                                        AION                                                Bevacizumab 1.25 mg                                                                                        AMD                                                                                                         34                    OS         20/70 (0.55)                                      20/200 (1.0)                                   6                                       No significant past medical history, on aspirin

  68/M/x                                         AION                                                Bevacizumab 10 mg/kg                                                                                                                                                                                                                                                                                      Visual acuity reduced                                                                  Renal cancer on interferon\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 5863726-9, 5872556-3

  69/F/x                                         AION                                                Bevacizumab 394 mg days 1 and 15                                                                                                                                                                                                                                                                                                                                                                 Breast cancer on capecitabine\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 5927943-1

  70/F/x                                         AION                                                Bevacizumab 1.25 mg                                                                                        DR                                                                                                                                                                                                                                                                                    DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 6155052-8

  71/F/72                                        AION                                                Bevacizumab                                                                                                                                                                                                                                                                                                                                                                                      Avastin Side Effects Report: 6367854-3

  72/F/47                                        Optic neuropathy                                    Bevacizumab systemic monthly       NA             NA                                NA          NA         Glioblastoma right frontotemporal            2 years after initial injection                                \>20 (monthly)        OU         20/200 (1) (amblyopia) OD\                        LP OD (3.3)\                                   30                                      
                                                                                                                                                                                                                                                                                                                                                             20/70 (0.55) OS                                   NLP (3.6) OS                                                                           

  73/M[@b42-opth-6-343]                          Optic neuropathy                                    Bevacizumab systemic               NA             NA                                NA          NA         Glioblastoma                                 NA                                                             8                     OU         NA                                                NA                                                                                     

  74/F/67[@b42-opth-6-343]                       Optic neuropathy                                    Bevacizumab systemic               NA             NA                                NA          NA         Glioblastoma                                 NA                                                             6                     OS         NA                                                NA                                                                                     

  75/F/59[@b42-opth-6-343]                       Optic neuropathy                                    Bevacizumab systemic               NA             NA                                NA          NA         Glioblastoma                                 NA                                                             7                     OU         NA                                                NA                                                                                     

  **Capillary occlusion**                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  76/F/58                                        Macular ischemia 1.25 mg                            Bevacizumab                        No             Nl                                Nl          No         Background DR                                2                                                              1                     OD         20/60 (0.5)                                       20/400 (1.3)                                   12                                      DM 1/2,350 anti-VEGF

  77/F/73                                        Macular ischemia                                    Bevacizumab 1.25 mg                No             NA                                NA          No         Pre-PDR                                      42                                                             0                     OS         20/80 (0.6)                                       20/80 (0.6)                                    3                                       DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/53 retrospective study of BRVO and diabetic maculopathy

  78/F/72                                        Macular ischemia                                    Bevacizumab 1.25 mg                No             NA                                NA          No         BRVO                                         28                                                             0                     OS         20/60 (0.5)                                       20/80 (0.6)                                    2                                       DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/53 retrospective study of BRVO and diabetic maculopathy

  79/M/66                                        Macular ischemia                                    Bevacizumab 1.25 mg                No             16                                10          Yes        CRVO/pre-PDR                                 4                                                              1                     OS         20/100 (0.7)                                      20/220 (1.04)                                  30                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1 of 1,500 anti-VEGF

  80/F/37[@b26-opth-6-343]                       Macular ischemia                                    Bevacizumab 1.25 mg                NA             NA                                NA          No         Vasculitis                                   7                                                              1                     OS         20/50 (0.4)                                       20/125 (0.8)                                   1                                       None

  81/M/40[@b35-opth-6-343]                       Macular ischemia                                    Bevacizumab 2.5 mg                 NA             NA                                NA          No         PDR                                          NA                                                             0                     OS         20/400 (1.3)                                      20/400 (1.3)                                                                           DM

  82/F/76[@b25-opth-6-343]                       Macular ischemia                                    Bevacizumab 1.25 mg                NA             NA                                NA          NA         CRVO ischemic                                28                                                             1                     OD         20/200 (1)                                        20/200 (1)                                     1                                       DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      CVA\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/300 of retinal vascular occlusion cases

  83/M/74[@b25-opth-6-343]                       Macular ischemia                                    Bevacizumab 1.25 mg                NA             NA                                NA          NA         CRVO ischemic                                28                                                             2                     OS         20/100 (0.7)                                      20/200 (1)                                     1                                       DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      MI\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/300 of retinal vascular occlusion cases

  84/M/58[@b29-opth-6-343]                       Macular ischemia                                    Bevacizumab 1.25 mg                No             NA                                NA          No         DM                                           21                                                             0                     OD         20/80 (0.6)                                       20/200 (1)                                     6                                       DM

  85/F/58                                        Macular ischemia                                    Bevacizumab 1.25 mg                No             20                                14          No         PDR/diffuse DM                               7                                                              0                     OD         20/200 (1)                                        20/80 (0.6)                                    3                                       HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/42 prospective study

  86/F/60                                        Macular ischemia                                    Bevacizumab 1.25 mg                No             18                                14          No         PDR/diffuse DM                               7                                                              0                     OS         20/200 (1)                                        20/120 (0.8)                                   3                                       HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/42 prospective study

  87/M/64                                        Macular ischemia                                    Bevacizumab 1.25 mg                No             20                                16          No         PDR/diffuse DM/vitreous hemorrhage           7                                                              0                     OD         CF3m (1.6)                                        20/80 (0.6)                                    3                                       HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Hepatic disease\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/42 prospective study

  88/F/65                                        Macular ischemia                                    Bevacizumab 1.25 mg                No             22                                14          No         PDR/diffuse DM                               7                                                              0                     OD         20/120 (0.8)                                      20/80 (0.6)                                    3                                       DM 1/42 prospective study

  89/M/64                                        Macular ischemia                                    Bevacizumab 1.25 mg                No             18                                14          No         PDR/ischemic DM                              7                                                              0                     OS         20/200 (1)                                        20/80 (0.6)                                    3                                       HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      DM 1/42 prospective study

  90/M/52                                        Macular ischemia                                    Bevacizumab 1.25 mg                No             24                                18          No         PDR/diffuse DM                               7                                                              0                     OD         20/200 (1)                                        20/120 (0.8)                                   3                                       DM 1/42 prospective study

  91/M/70                                        Hemorrhagic macular infarction; worsening CRVO      Bevacizumab 1.25 mg                NA             NA                                15          No         CRVO                                         21                                                             0                     OS         20/100 (0.7)                                      20/320 (1.2)                                   1                                       None 1/2,000

  92/M/65[@b23-opth-6-343]                       Conversion of nonischemic CRVO into ischemic CRVO   Bevacizumab 1.25 mg                NA             NA                                NA          NA         CRVO                                         21                                                             1                     OD         20/50 (0.4)                                       20/800 (1.6)                                   6                                       DM

  93[@b44-opth-6-343]                            Capillary occlusion\                                Bevacizumab intravitreal                                                                                                                                                                                                                                                                                                                                                                         
                                                 Cotton wool spot                                                                                                                                                                                                                                                                                                                                                                                                                                     

  94[@b37-opth-6-343]                            Capillary ischemia                                  Bevacizumab 1.25 mg                No             NA                                NA          No         Nonischemic BRVO                             1 month                                                        0                     NA         NA                                                NA                                             1                                       1/37 nonischemic branch retinal vein occlusion

  95[@b37-opth-6-343]                            Capillary ischemia                                  Bevacizumab 1.25 mg                No             NA                                NA          No         Nonischemic BRVO                             1 month                                                        0                     NA         NA                                                NA                                             1                                       1/37 nonischemic branch retinal vein occlusion

  96[@b37-opth-6-343]                            Capillary ischemia                                  Bevacizumab 1.25 mg                No             NA                                NA          No         Nonischemic BRVO                             1 month                                                        0                     NA         NA                                                NA                                             1                                       1/37 nonischemic branch retinal vein occlusion

  97/F/62[@b37-opth-6-343]                       Capillary ischemia                                  Bevacizumab 1.25 mg                No             NA                                NA          No         Ischemic BRVO                                1 month                                                        0                     OS         20/120 (0.8)                                      20/200 (1.0)                                   1                                       1 of 21 with ischemic BVO

  98[@b41-opth-6-343]                            Retinal ischemia                                    Bevacizumab 1.25 mg                NA             NA                                NA          NA         CRVO                                         NA                                                             NA                    NA         NA                                                NA                                                                                     1/186 total patients in 1 center (1/9 eyes with CRVO, 0/173 eyes with AMD)

  99/M/66                                        Capillary occlusion\                                Bevacizumab 1.25 mg                No             14                                24          No         AMD                                          30                                                             1                     OS         20/200 (1)                                        20/200 (1)                                     36                                      Gout 1/2,500
                                                 Cotton wool spot                                                                                                                                                                                                                                                                                                                                                                                                                                     

  100/F/74                                       Capillary occlusion\                                Bevacizumab 1.25 mg                No             11                                23          No         Idiopathic foveal telangiectasia             60                                                             1                     OS         20/80 (0.6)                                       20/70 (0.55)                                   36                                      HTN 1/2,500
                                                 Cotton wool spot                                                                                                                                                                                                                                                                                                                                                                                                                                     

  101/F/27                                       Capillary occlusion                                 Bevacizumab 1.25 mg                No             NA                                NA          No         Retinal vasculitis                           14                                                             1                     OU         20/20 (0)                                         20/20 (0)                                      1                                       No 1/19,158

  **Miscellaneous**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  102/M/55                                       Ophthalmic artery occlusion                         Bevacizumab 1.25 mg                Yes            NA                                NA          Yes        PDR/NVG                                      3                                                              1                     OS         20/200 (1)                                        NLP (3.6)                                      3                                       DM, carotid artery occlusion\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1/256 bevacizumab

  103/F/40                                       Choroidal infarction, HTN retinopathy               Bevacizumab 15 mg/kg q3wk                                                                                                                                                                                                                                                                                                                                                                        Glioma, HTN Avastin Side Effects Report: 4969093-7

  104[@b24-opth-6-343]                           Visual loss                                         Bevacizumab                        NA             NA                                NA          NA         PDR                                          21                                                             NA                    NA         NA                                                NA                                                                                     DM

  105/M/78                                       Retinal artery spasm                                Bevacizumab 5 mg/kg q2wk                                                                                                                                                                                                                                                                                                                                                                         Colon cancer on oxaliplatin avastin Side Effects Report: 5407594-8

  106/M/x                                        Retinal artery spasm                                Bevacizumab 5 mg/kg q2wk                                                                                                                                                                                                                                Tunnel vision                                                                                                                            Colon cancer; obesity on oxaliplatin Avastin Side Effects Report: 5442353-1
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Red, prospective study data; blue, literature data; black, retrospective collaborative case series; black underlined, data reported to FDA till 2009 and eHealthMe from FDA and community for 2010 and late 2009.

**Abbreviations:** AMD, wet age-related macular degeneration; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; DM, diabetic maculopathy (in column of eye disease); NA, not assessed; Nl, normal; DM, diabetes mellitus (in column of systemic disease); HTN, systemic hypertension; CAD, coronary artery disease; CRAO, central retinal artery occlusion; BRAO, branch retinal artery occlusion; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; AION, anterior ischemic optic neuropathy; CME, cystoid macular edema; NVG, neovascular glaucoma; IOP, intraocular pressure; OD, right eye; OS, left eye; OU, bilateral; HM, hand motion; LP, light perception; NLP, no light perception.

###### 

Collaborative and literature review of 38 cases of ocular vascular complications of VEGF antagonists excluding bevacizumab (ranibizumab and pegaptanib): clinical profile

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case N./sex/age                                              Ocular vascular event after        Dose used (mL)       Paracentesis   IOP at discharge post injection   Prior IOP   Glaucoma   Primary eye disease        Interval injection to detection of vascular occlusion (days)   N. prior injections   OD or OS   Visual acuity prior to vascular event (log MAR)   Visual acuity after vascular event (log MAR)   Follow up after ocular event (months)   Systemic disease and risk of the vascular event per submitting author (new cases per total number of injected patients)
  ------------------------------------------------------------ ---------------------------------- -------------------- -------------- --------------------------------- ----------- ---------- -------------------------- -------------------------------------------------------------- --------------------- ---------- ------------------------------------------------- ---------------------------------------------- --------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  Arterial occlusion                                                                                                                                                                                                                                                                                                                                                                                                                                               

  1/M/75                                                       CRAO                               Ranibizumab 0.5 mg   No             Nl                                NA          No         Ischemic CRVO              30                                                             1                     OS         20/400 (1.3)                                      LP (3.3)                                       2                                       DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   CAD\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1/2,400 anti-VEGF\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1/16 ROCC study[@b63-opth-6-343]

  2/M/67                                                       CRAO                               Ranibizumab 0.5 mg   No             15                                15          No         DM                         30                                                             4                     OS         20/100 (0.7)                                      20/400 (1.3)                                   12                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1/6,478 anti-VEGF

  3[@b30-opth-6-343]                                           CRAO                               Ranibizumab          NA             NA                                NA          NA         DM                         NA                                                             NA                    NA         NA                                                NA                                             12                                      DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1/102 eyes prospective study (RESOLVE)

  4/M/85 (Reimao[\*](#tfn4-opth-6-343){ref-type="table-fn"})   CRAO                               Ranibizumab 0.5 mg   No             38 mmHg                           NA          Yes        NVG                        2d                                                             0                     OD         20/25 (0.1)                                       20/80 (0.6)                                                                            HTN\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   COPD\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ex-smoker\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   bilateral carotid stenosis

  5/F/81                                                       Retinal artery occlusion           Ranibizumab                                                                                                                                                                                                                                                                                                                                                      Lucentis Side Effects Report: 6109626-0

  6/F/x                                                        Retinal artery occlusion           Ranibizumab 0.5 mg                                                                                                                                                                                                                                                                                                                                               HTN, CAD\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Lucentis Side Effects Report: 6184843-2

  7/M/84                                                       Retinal artery occlusion           Ranibizumab 0.5 mg                  High IOP                                                 AMD                                                                                                                                                                                                                                                                 Lucentis Side Effects Report: 6210113-X

  8/F/70                                                       Retinal artery occlusion           Ranibizumab                                                                                                                                                                                                                                                                                                                                                      Lucentis Side Effects Report: 6480905-0, 6496635-5

  9/F/70                                                       Retinal artery occlusion           Ranibizumab 0.5 mg                                                                                                                                                                                                                                                                                                                                               Lucentis Side Effects Report: 6207699-8

  10/F/86                                                      Retinal artery occlusion           Pegaptanib                                                                                                                                                                                                                                                                                                                                                       HTN, dyslipidemia\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Macugen Side Effects Report: 5248582-4, 5224175-X

  11/M/67                                                      Retinal artery occlusion           Pegaptanib                                                                                                                                                                                                                                                                                                                                                       Macugen Side Effects Report: 6108967-0

  12/F/above 60 years                                          Retinal artery occlusion           Ranibizumab                                                                                  AMD                        \<1 month                                                                                                                                                                                                                                2010 events from eHealthMe drug outcomes from FDA and community

  Venous occlusion                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  13/M/84                                                      Retinal vein occlusion             Ranibizumab 0.5 mg                                                                                                                                                                                                                                                                                                                                               Lucentis Side Effects Report: 5216324-4/5889807-1

  14/M/74                                                      Retinal vein occlusion             Ranibizumab                                                                                                                                                                                                                                                                                                                                                      Lucentis Side Effects Report: 5253885-3/5259058-2

  Retinal vascular occlusion (unspecified)                                                                                                                                                                                                                                                                                                                                                                                                                         

  15^37c^                                                      Ocular vascular occlusion          Ranibizumab 0.5 mg   NA             NA                                NA          NA         DM                         NA                                                             NA                    NA         NA                                                NA                                                                                     DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1/375 for diabetic CME

  16^37c^                                                      Ocular vascular occlusion          Ranibizumab 0.5 mg   NA             NA                                NA          NA         DM                         NA                                                             NA                    NA         NA                                                NA                                                                                     DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1/375 for diabetic CME

  17^37c^                                                      Ocular vascular occlusion          Ranibizumab 0.5 mg   NA             NA                                NA          NA         DM                         NA                                                             NA                    NA         NA                                                NA                                                                                     DM\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1/375 for diabetic CME

  18/M/47                                                      Retinal vascular disorder          Ranibizumab 0.3 mg                                                                           CME                                                                                                                                                                                                                                                                 Lucentis Side Effects Report: 5896098-4

  19/M/x                                                       Retinal vascular disorder          Ranibizumab                                                                                                                                                                                                                                                                                                                                                      Lucentis Side Effects Report: 6180863-2

  20/F/66                                                      Retinal vascular disorder          Pegaptanib                                                                                   AMD                                                                                                                                                                                                                                                                 Macugen Side Effects Report: 6409650-4

  21/M/60                                                      Retinal vascular disorder          Pegaptanib 0.3 mg                                                                            AMD                                                                                                                                                                                                                                                                 Macugen Side Effects Report: 6463543-5

  22/Above 60 years                                            Retinal vascular disorder          Pegaptanib                                                                                   AMD                                                                                                                                                                                                                                                                 Late 2009 events from eHealthMe drug outcomes from FDA and community

  23--28/6 cases above 60 years                                Retinal vascular disorder          Ranibizumab                                                                                  mixed                                                                                                                                                                                                                                                               2010 events from eHealthMe drug outcomes from FDA and community

  **Optic neuropathy**                                                                                                                                                                                                                                                                                                                                                                                                                                             

  29/M/75                                                      AION                               Ranibizumab 0.5 mg                                                                           AMD                                                                                       4                     OS         20/40                                             20/60                                          1                                       HTN, hypothyroidism, BPH, angina, on amlodipine, levothyroxine, temazepam, nitroglycerin\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   1/4500 antiVEGF injection

  30/F/70^37a^                                                 AION OU                            Pegaptanib           No             NA                                NA          No         AMD OD                     7d OD                                                          0                     OD         20/40 (0.3)                                       20/4000 (2.2)                                  3                                       DM

  Diabetic prophylaxis for cataract surgery OS                 4d OS                              OS                   NA             20/200 (1)                        3           HTN                                                                                                                                                                                                                                                                            

  31/M/93                                                      AION                               0.3 mg Pegaptanib                                                                                                                                                                                                                                                         Visual acuity reduced                                                                  Macugen Side Effects Report: 4825003-4

  32/M/72                                                      AION                               Pegaptanib                                                                                   AMD                                                                                                                                                                                                                                                                 Macugen Side Effects Report: 4982605-2

  Capillary occlusion                                                                                                                                                                                                                                                                                                                                                                                                                                              

  33/F/x                                                       Retinal ischemia (macular)         Ranibizumab                                                                                                                                                                                                                                                                                                                                                      Lucentis Side Effects Report: 5889807-1

  34/F/x                                                       Retinal ischemia (macular)         Ranibizumab 0.5 mg                                                                                                                                                                                                                                                                                                                                               Lucentis Side Effects Report: 6454819-6

  35[@b30-opth-6-343]                                          Capillary occlusion (peripheral)   Ranibizumab          NA             NA                                NA          NA         DM                         NA                                                             NA                    NA         NA                                                NA                                             12                                      DM 1/102 eyes prospective study (RESOLVE)

  36/F/x                                                       Retinal ischemia (peripheral)      Ranibizumab 0.5 mg                                                                                                                                                                                                                                                                                                       9                                       Lucentis Side Effects Report: 6037721-3; patient died 9 months after injection

  37/above 60 years                                            Retinal ischemia                   Ranibizumab                                                                                  Unspecified                                                                                                                                                                                                                                                         2010 events from eHealthMe drug outcomes from FDA and community

  Miscellaneous                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  38/M/85                                                      Diffuse vascular occlusion         Ranibizumab 0.5 mg   No             NA                                15          No         Ocular ischemic syndrome   14                                                             1                     OD         20/100 (0.7)                                      LP (3.3)                                       10                                      Carotid stenosis
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Red, prospective study data; blue, literature data; black, retrospective collaborative case series; black underlined, data reported to FDA till 2009 and eHealthMe from FDA and community for 2010 and late 2009;

Reimao reference refers to eposter EP-GLA-405 SOE 2011 Geneve presented by Reimao P, Macedo M, Gomes M, Maia S, Santos M, Meneres MJ, from Portugal.

**Abbreviations:** AMD, wet age-related macular degeneration; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; DM, diabetic maculopathy (in column of eye disease); NA, not assessed; Nl, normal; DM, diabetes mellitus; HTN, systemic hypertension; CAD, coronary artery disease; CRAO, central retinal artery occlusion; BRAO, branch retinal artery occlusion; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; AION, anterior ischemic optic neuropathy; IOP, intraocular pressure; OD, right eye; OS, left eye; CME, cystoid macular edema; NVG, neovascular glaucoma.

###### 

Retinal vasoconstriction values in subjects with ocular vascular events during bevacizumab therapy in 13 eyes, and intravitreal ranibizumab therapy in one eye

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case/sex/age   Ocular vascular event after   Bevacizumab (mg)   Primary eye disease        Interval injection to last fluorescein angiography (days)   N. prior injections   Systemic disease             Arterial vasoconstriction from baseline 1.0       Venous vasoconstriction from baseline 1.0
  -------------- ----------------------------- ------------------ -------------------------- ----------------------------------------------------------- --------------------- ---------------------------- ------------------------------------------------- -------------------------------------------------
  1/F/74         CRAO                          1.25               Ischemic CRVO              14                                                          1                     Smoker (heavy)               0.93                                              0.68[\*](#tfn7-opth-6-343){ref-type="table-fn"}

  2/F/27         Capillary occlusion           1.25               Retinal vasculitis         14                                                          1                     No                           0.46[\*](#tfn7-opth-6-343){ref-type="table-fn"}   0.73

  3/M/93         CRVO                          1.25               CNV                        10                                                          1                     HTN\                         0.90                                              1.35[+](#tfn8-opth-6-343){ref-type="table-fn"}
                                                                                                                                                                               CAD carotid artery disease                                                     

  4/M/66         Capillary occlusion CWS       1.25               CNV                        30                                                          1                     Gout                         0.96                                              0.84

  5/M/51         AION                          1.25               CNV                        15                                                          1                     Pseudoxanthoma elasticum     0.72[\*](#tfn7-opth-6-343){ref-type="table-fn"}   0.88

  6/F/76         Macular ischemia              1.25               CRVO ischemic              28                                                          1                     DM\                          1.03                                              0.95
                                                                                                                                                                               CVA                                                                            

  7/M/74         Macular ischemia              1.25               CRVO ischemic              28                                                          2                     DM\                          1.03                                              0.93
                                                                                                                                                                               MI                                                                             

  8/M/65         BRVO                          1.25               PDR                        7                                                           0                     HTN\                         0.22[\*](#tfn7-opth-6-343){ref-type="table-fn"}   0.67[\*](#tfn7-opth-6-343){ref-type="table-fn"}
                                                                                                                                                                               DM                                                                             

  9/M/63         BRVO                          1.25               PDR                        7                                                           0                     HTN\                         0.43[\*](#tfn7-opth-6-343){ref-type="table-fn"}   0.85
                                                                                                                                                                               DM                                                                             

  10/F/60        Macular ischemia              1.25               PDR                        7                                                           0                     HTN\                         0.83                                              1.82
                                                                                                                                                                               DM                                                                             

  11/M/64        Macular ischemia              1.25               PDR                        7                                                           0                     HTN\                         1.01                                              0.88
                                                                                                                                                                               DM\                                                                            
                                                                                                                                                                               Hepatic disease                                                                

  12/M/64        Macular ischemia              1.25               PDR                        7                                                           0                     HTN\                         0.95                                              0.85
                                                                                                                                                                               DM                                                                             

  13/M/52        Macular ischemia              1.25               PDR                        7                                                           0                     DM                           Not measurable                                    0.97

  14/M/85        Diffuse vascular occlusion    Lucentis 0.5 mg    Ocular ischemic syndrome   14                                                          1                     Carotid stenosis complete    0.58[\*](#tfn7-opth-6-343){ref-type="table-fn"}   0.84
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Red, intravitreal ranibizumab;

refers to marked constriction;

indicates that this value not counted because it was part of CRVO.

**Abbreviations:** PDR, proliferative diabetic retinopathy; NA, not assessed; CNV, choroidal neovascularization; DM, diabetes mellitus; HTN, systemic hypertension; CAD, coronary artery disease; MI, myocardial infarction; CVA, cerebrovascular accident; CRAO, central retinal artery occlusion; BRAO, branch retinal artery occlusion; CRVO, central retinal vein occlusion; BRVO, branch retinal vein occlusion; AION, anterior ischemic optic neuropathy.
